Austria suspends batch of AstraZeneca vaccine COVID-19 after death

Austrian authorities suspended inoculations with a batch of AstraZeneca’s COVID-19 vaccine as a precaution while investigating the death of one person and the illness of another after the vaccines, a health agency said on Sunday. BASG) received two reports in a temporal connection with a vaccination of the same batch of the AstraZeneca vaccine at the district clinic of Zwettl “in the province of Lower Austria, he said. He has developed a pulmonary embolism and is recovering, he said. Pulmonary embolism is an acute lung disease caused by a dislodged blood clot. “Currently there is no evidence of a causal relationship with vaccination,” said BASG. , as well as the ORF broadcaster and the APA news agency reported that the women were nurses working at the Zwettl clinic. BASG said blood clotting was not among the known side effects of the vaccine. any possible link. “As a precautionary measure, the remaining stocks of the affected vaccine batch are not the more being issued or vaccinated, “he added.

An AstraZeneca spokesman said: “There have been no confirmed serious adverse events associated with the vaccine”, adding that all batches are subject to strict and stringent quality controls. Actual tests and experiences so far suggest that the vaccine is safe and effective, and has been approved for use in more than 50 countries, he said. AstraZeneca also said it was in contact with the Austrian authorities and would fully support the investigation. European Union regulators approved the product in late January, saying it was effective and safe to use, while the World Health Organization (WHO) in mid-February listed the product for emergency use. The adverse reactions observed in the trials were mostly short-lived and no blood clotting problems were reported. A safety assessment by the German vaccine regulator of more than 360,000 people who received the AstraZeneca vaccine in the country between the launch in early February and February 26 concluded that the adverse reactions were in line with the safety profile described in trials clinical features.